Acorda's novel approach to MS therapy attracts attention
This article was originally published in Scrip
Amid speculation that Biogen Idec is looking to buy Acorda Therapeutics to gain access to its investigational oral multiple sclerosis candidate, fampridine-SR (4-aminopyridine), intriguing Phase III data demonstrating the drug's effects on patients' walking abilities were published in the February 28th issue of The Lancet.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.